Personalizing Immune Checkpoint Inhibitor Therapy
This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.
Checked against the public recordLast updated Sep 24, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Holy Cross Hospital, Maryland
- Interventions being studied
- Other: Blood and tumor tissue analysis, Clinical response.
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the intent to receive therapy with immune checkpoint inhibitors * Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy * Informed consent Exclusion Criteria: • Lack of informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Holy Cross HospitalSilver Spring, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 24, 2020. Always confirm current availability with the study team.